Drug Profile
SER 100
Alternative Names: SER-100; SER100 PH; SER100 TR-ISH; ZP-120Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Zealand Pharma
- Developer Serodus; Zealand Pharma
- Class Oligopeptides; Peptides
- Mechanism of Action Nociceptin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Isolated systolic hypertension
- No development reported Pulmonary hypertension
- Discontinued Decompensated heart failure
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Pulmonary-hypertension(In volunteers) in Norway (IV, Infusion)
- 16 Jan 2016 Phase-I clinical trials in Pulmonary hypertension (In volunteers) in Norway (IV) before January 2016
- 09 Sep 2014 Efficacy and adverse events data from a phase IIa trial in Isolated systolic hypertension released by Serodus